Cargando…
Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade?
British Journal of Cancer (2002) 86, 1664–1664. DOI: 10.1038/sj/bjc/6600314 www.bjcancer.com © 2002 Cancer Research UK
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746592/ http://dx.doi.org/10.1038/sj.bjc.6600314 |
_version_ | 1782172053445541888 |
---|---|
author | de Wit, R Stoter, G Sparreboom, A Verweij, J de Boer, A C vd Linden, G H M |
author_facet | de Wit, R Stoter, G Sparreboom, A Verweij, J de Boer, A C vd Linden, G H M |
author_sort | de Wit, R |
collection | PubMed |
description | British Journal of Cancer (2002) 86, 1664–1664. DOI: 10.1038/sj/bjc/6600314 www.bjcancer.com © 2002 Cancer Research UK |
format | Text |
id | pubmed-2746592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-27465922009-09-18 Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade? de Wit, R Stoter, G Sparreboom, A Verweij, J de Boer, A C vd Linden, G H M Br J Cancer Letter to the Editor British Journal of Cancer (2002) 86, 1664–1664. DOI: 10.1038/sj/bjc/6600314 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-05-20 2002-05-03 /pmc/articles/PMC2746592/ http://dx.doi.org/10.1038/sj.bjc.6600314 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Letter to the Editor de Wit, R Stoter, G Sparreboom, A Verweij, J de Boer, A C vd Linden, G H M Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade? |
title | Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade? |
title_full | Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade? |
title_fullStr | Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade? |
title_full_unstemmed | Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade? |
title_short | Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade? |
title_sort | reply: granisetron vs ondansetron: is it a question of duration of 5-ht(3) receptor blockade? |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746592/ http://dx.doi.org/10.1038/sj.bjc.6600314 |
work_keys_str_mv | AT dewitr replygranisetronvsondansetronisitaquestionofdurationof5ht3receptorblockade AT stoterg replygranisetronvsondansetronisitaquestionofdurationof5ht3receptorblockade AT sparrebooma replygranisetronvsondansetronisitaquestionofdurationof5ht3receptorblockade AT verweijj replygranisetronvsondansetronisitaquestionofdurationof5ht3receptorblockade AT deboerac replygranisetronvsondansetronisitaquestionofdurationof5ht3receptorblockade AT vdlindenghm replygranisetronvsondansetronisitaquestionofdurationof5ht3receptorblockade |